Stephen Liu, Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared on X:
“Update on I-SPY2 trial JAMA Oncology from Claudine Isaacs, MedStar Georgetown, Georgetown Lombardi, shows that combining cemiplimab (PD-1) and fianlimab (LAG3) to neoadjuvant paclitaxel for early stage breast cancer improves pCR including in triple-negative and HR+.”
Title: Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer
Authors: Claudine Isaacs, Rita Nanda, Christina Yau, A. Jo Chien, Dawn L. Hershman, Erica M. Stringer-Reasor, Anne M. Wallace, Alexandra Thomas, Christos Vaklavas, Amy S. Clark, Laura C. Kennedy, Amy Sanford, Judy C. Boughey, Kathy S. Albain, Lajos Pusztai, Kevin M. Kalinsky, Heather Beckwith, Nicole O. Williams, Hyo S. Han, MD, Carla Falkson, Mili Arora, Anthony D. Elias, Paula R. Pohlmann, Mariya Rozenblit, Natalie Marshall, Yunn-Yi Chen, Meghna S. Trivedi, Julia E. McGuinness, Frederick M. Howard, Nan Chen, Katia Khoury, Rachael B. Lancaster, Kay T. Yeung, Emily Douglas, Mei Wei, Candace Mainor, Barbara LeStage, Amy L. Delson, Adam L. Asare, Lamorna Brown-Swigart, Gillian L. Hirst, Jeffrey B. Matthews, Jane Perlmutter, W. Fraser Symmans, Douglas Yee, Nola M. Hylton, Laura J. van ’t Veer, Hope S. Rugo, Angela M. DeMichele, Donald A. Berry, Laura J. Esserman.
Read the full article.
This also can be interesting:
HER2-Low and HER2-Ultralow: What the Categories Change
